Small anticancer drug release by light: Photochemical internalization of porphyrin-β-cyclodextrin nanoparticles.


Journal

Carbohydrate polymers
ISSN: 1879-1344
Titre abrégé: Carbohydr Polym
Pays: England
ID NLM: 8307156

Informations de publication

Date de publication:
15 Apr 2023
Historique:
received: 29 08 2022
revised: 24 11 2022
accepted: 10 12 2022
entrez: 6 2 2023
pubmed: 7 2 2023
medline: 9 2 2023
Statut: ppublish

Résumé

Aiming to engineer simple, neutral, strongly amphiphilic photoactive nanoparticles (NPs) to specifically target cancer cell lysosomes for drug transport and light-controlled release, new conjugates of β-cyclodextrin with highly hydrophobic triphenylporphyrin bearing different alkyl chains, were synthesized. Although differently sized, all conjugates self-assemble into ~60 nm NPs in water and display similar photoactivity. The NPs target selectively the lysosomes of breast adenocarcinoma MCF-7 cells, embedding in vesicular membranes, as experiments with model liposomes indicate. Either empty or drug-loaded, the NPs lack dark toxicity for 48 h. They bind with differently structured anticancer drugs tamoxifen and gemcitabine as its N-adamantyl derivative. Red light irradiation of cells incubated with drug-loaded NPs results in major reduction of viability (>85 %) for 48 h displaying significant synergy of photo-chemotoxicity, as opposed to empty NPs, and to loaded non-irradiated NPs, in manifestation of photochemical internalization (PCI). Our approach expands the field of PCI into different small molecule chemotherapeutics.

Identifiants

pubmed: 36746578
pii: S0144-8617(23)00043-7
doi: 10.1016/j.carbpol.2023.120579
pii:
doi:

Substances chimiques

Porphyrins 0
Antineoplastic Agents 0
Gemcitabine 0
beta-Cyclodextrins 0
Drug Carriers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120579

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest There are no conflicts to declare.

Auteurs

Stylianos Panagiotakis (S)

Institute of Nanoscience and Nanotechnology, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: s.panagiotakis@inn.demokritos.gr.

Barbara Mavroidi (B)

Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: bmavroidi@bio.demokritos.gr.

Alexandros Athanasopoulos (A)

Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: alexandr@bio.demokritos.gr.

Antonio Ricardo Gonçalves (AR)

Institute of Nanoscience and Nanotechnology, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: aricardo7@gmail.com.

Loïc Bugnicourt-Moreira (L)

University of Lyon, CNRS, UMR 5223, IMP, UCBL, 15 bd André Latarjet, F-69622 Villeurbanne, France. Electronic address: loic.bugnicourt@hotmail.com.

Theo Regagnon (T)

University of Lyon, CNRS, UMR 5223, IMP, UCBL, 15 bd André Latarjet, F-69622 Villeurbanne, France. Electronic address: tregagnon@hotmail.fr.

Nikos Boukos (N)

Institute of Nanoscience and Nanotechnology, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: n.boukos@inn.demokritos.gr.

George Charalambidis (G)

Laboratory of Bioinorganic Chemistry, Department of Chemistry, University of Crete, Voutes Campus, 70013 Heraklion, Crete, Greece. Electronic address: gcharal@uoc.gr.

Athanasios G Coutsolelos (AG)

Laboratory of Bioinorganic Chemistry, Department of Chemistry, University of Crete, Voutes Campus, 70013 Heraklion, Crete, Greece. Electronic address: acoutsol@uoc.gr.

Mantas Grigalavicius (M)

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital - Radium Hospital, 0379 Oslo, Norway. Electronic address: mangri@rr-research.no.

Theodossis A Theodossiou (TA)

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital - Radium Hospital, 0379 Oslo, Norway. Electronic address: Theodossis.Theodossiou@rr-research.no.

Kristian Berg (K)

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital - Radium Hospital, 0379 Oslo, Norway. Electronic address: Kristian.Berg@rr-research.no.

Catherine Ladavière (C)

University of Lyon, CNRS, UMR 5223, IMP, UCBL, 15 bd André Latarjet, F-69622 Villeurbanne, France. Electronic address: Catherine.Ladaviere@univ-lyon1.fr.

Maria Pelecanou (M)

Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: pelmar@bio.demokritos.gr.

Konstantina Yannakopoulou (K)

Institute of Nanoscience and Nanotechnology, National Center for Scientific Research "Demokritos", Aghia Paraskevi 15341, Attiki, Greece. Electronic address: k.yannakopoulou@inn.demokritos.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH